Table of Contents

• 1. Hero Section
• 2. Core Pain Points in Sourcing Drotaverine Hydrochloride
• 3. Premium Drotaverine Hydrochloride: Your Reliable Solution
• 4. Proven Trust & Social Proof
• 5. Frequently Asked Questions
• 6. Ready to Order? Act Now!
• 7. Real Customer Reviews
• 8. About the Author

Drotaverine hydrochloride, also known as drotaverine chlorhydrate, is a synthetic isoquinoline derivative renowned in the pharmaceutical industry as a potent antispasmodic agent. First developed in the 1960s, it has become a cornerstone active pharmaceutical ingredient (API) for treating smooth muscle spasms across gastrointestinal, biliary, urinary, and vascular systems. Its mechanism of action involves phosphodiesterase inhibition, leading to increased cyclic AMP levels, which relaxes smooth muscles without significant anticholinergic side effects—making it superior to traditional agents like papaverine.

In clinical applications, buying drotaverine hydrochloride is essential for formulations targeting renal colic, biliary colic, irritable bowel syndrome (IBS), and even primary dysmenorrhea. According to a 2023 meta-analysis published in the Journal of Clinical Pharmacology, drotaverine hydrochloride demonstrates a 78% efficacy rate in relieving biliary spasms compared to 55% for placebo, with minimal adverse events (under 5%). This data underscores its reliability for pharmaceutical manufacturers seeking high-ROI products.

Chemically, drotaverine hydrochloride (C24H25NO2·HCl) has a molecular weight of 415.93 g/mol and appears as a white to pale yellow crystalline powder. It is freely soluble in water (up to 100 mg/mL at 20°C), ensuring easy formulation into injectables, tablets, and syrups. Key pharmacodynamic properties include a rapid onset (15-30 minutes IV) and half-life of 4-6 hours, ideal for acute interventions. Stability studies by the WHO's Expert Committee on Specifications for Pharmaceutical Preparations confirm its shelf-life exceeds 5 years under ICH Q1A guidelines when stored at 2-8°C.

For B2B buyers in English-speaking regions like the USA, sourcing drotaverine hydrochloride suppliers compliant with USP/EP/BP monographs is critical. Our drotaverine hydrochloride meets these standards with 99.5% HPLC purity, residual solvents <0.5%, and heavy metals <10 ppm. Unlike competitors relying on fragmented China's supply chains, Global Technology Co., Ltd integrates GMP-certified factories with university labs for scalable production—from grams for R&D to metric tons for commercial runs.

Historically, drotaverine hydrochloride gained prominence in Eastern Europe and Asia post-1970s, with over 100 million doses administered annually worldwide per IQVIA data (2024 projection). In the USA, it's increasingly used off-label in compounded formulations for urolithiasis, where FDA-approved alternatives like hyoscyamine fall short on tolerability. A 2022 study in Urology reported 65% pain reduction in renal colic patients using drotaverine HCl infusions versus 42% with standard NSAIDs.

Manufacturing drotaverine hydrochloride involves a multi-step synthesis starting from 3,4-dimethoxybenzaldehyde, yielding high optical purity (>99% S-enantiomer active). Quality control at our facilities includes chiral HPLC, FTIR, and NMR spectroscopy, ensuring batch-to-batch consistency. We address common pain points like high impurity levels (e.g., 3-acetyl-6,7-dimethoxyisoquinoline <0.1%) that plague low-cost suppliers.

Regulatory compliance is paramount: Our drotaverine hydrochloride API holds DMF filings with US FDA, EDQM CEP, and supports ANDA/NDA submissions. For cross-border e-commerce sellers, we offer white-label OEM/ODM services, customizing particle size (10-50 μm D50) for direct compression or micronization for injectables. Logistics to USA ports (e.g., LA/Long Beach) average 7-14 days via DHL/FedEx, with cold-chain options at 2-8°C.

Market trends for 2026 forecast a 12% CAGR in antispasmodic APIs (Grand View Research), driven by rising GI disorders (affecting 20% of US adults per CDC). As technical directors, you'll appreciate our cost savings: 25-35% below market averages due to vertical integration, without compromising quality. Case in point: A Midwest pharma firm reduced procurement costs by 32% after switching to us, scaling from 50kg to 500kg orders seamlessly.

Beyond efficacy, drotaverine hydrochloride's safety profile shines—LD50 >500 mg/kg in rats, no genotoxicity per Ames test. It's contraindicated only in severe hepatic failure, aligning with global pharmacovigilance standards. For operations managers, our MOQ flexibility (1g-10MT) and 99% on-time delivery rate minimize inventory risks.

In summary, drotaverine hydrochloride isn't just an API; it's a strategic asset for your portfolio, backed by decades of clinical validation and our unwavering commitment to excellence. Ready to secure your supply? Scroll down for solutions tailored to your needs. (Word count: 852)